Cloud Labs Remain Small but Growth Is Accelerating, with Limited Near-Term Impact on CROs and Instrument OEMs
AI summary card
Cloud Labs Remain Small but Growth Is Accelerating, with Limited Near-Term Impact on CROs and Instrument OEMs
Morgan Stanley's interview with a cloud lab CEO indicates that cloud labs improve wet-lab efficiency through 24/7 operations, algorithmic reproducibility, and high instrument utilization, but at this stage customers are concentrated among leading pharmaceutical companies; near term, they are more likely to divert in-house pharma lab work than to materially disrupt CROs or instrument OEMs.
- Cloud labs operate like a 'wet-lab foundry': scientists design experiments via software APIs, and centralized facilities execute the protocols using automation and manual steps.
- Current customers almost entirely come from the top 10-20 large pharmaceutical companies, with the business focused on late-stage development and quality testing; consumer goods, semiconductor, and academic customers have been strategically deprioritized.
- The core value comes from 24/7/365 operations, 75%-80% instrument utilization, complete metadata capture in software, and a cost-efficiency advantage versus the roughly 15% utilization typical of traditional in-house pharma labs.
- The expert company's revenue has doubled every year over the past three years, with about half of growth coming from new customers and half from existing customers; growth over the next 1-3 years will mainly be driven by same-site sales ramp.
- The expert believes near-term disruption to CROs and instrument OEMs is small, but CROs may eventually build competitive cloud labs of their own.
Report interpretation
Overview
This report is based on a recent Morgan Stanley expert call with the CEO of a leading cloud lab, discussing the cloud lab business model in wet-lab research, customer structure, instrument and consumables exposure, sources of efficiency, growth cadence, and potential impact on CROs and scientific instrument OEMs. Covering the North American Life Science Tools & Diagnostics industry, the conclusion is neutral: the cloud lab model has efficiency and reproducibility advantages, revenue growth is accelerating, but the market is still early and small in scale, so near-term industry disruption is limited.
Core views
Cloud labs essentially turn wet-lab research into a centrally executed process driven by software APIs, similar to a contract manufacturing factory for experiments. Their current commercial focus is concentrated in large pharmaceutical companies, especially in late-stage development and quality testing, with core work including sample preparation, loading analytical instruments, chromatography/mass spectrometry, and some nuclear magnetic resonance experiments. The expert believes cloud lab growth in the near term mainly comes from workloads shifting out of internal pharma labs, rather than from taking substantial share from CROs or instrument OEMs; meanwhile, because customers care about reproducibility with the same method, cloud labs do not frequently upgrade instruments, so they are unlikely to be a major driver of instrument replacement cycles.
Analysis framework
The report uses an expert-interview format, starting from the operating perspective of a leading cloud lab CEO, to map customer profiles, experiment types, supplier exposure, operating efficiency, sources of revenue growth, attitudes toward AI and data security, and then translate this information into implications for the life science tools, CRO, and instrument OEM industries.
Methodology notes
Using interviews with industry operators to identify the commercialization progress and industry-chain impact of emerging laboratory models.
The report does not use a traditional financial valuation model; instead, it relies on an expert call as the core evidence, focusing on cloud lab customer mix, unit economics, supplier dependence, and potential substitution relationships.
Assessing the share-shift path from new models to in-house pharma labs, CROs, and instrument OEMs.
The expert believes cloud labs mainly substitute for internal pharma lab workload in the near term, with limited impact on CROs and instrument OEMs; however, if CROs build cloud labs in the future, the competitive landscape could change.
Asset mapping & comparison
Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).
- TMOInstrument and consumables supplier exposure
- Strengths
- Mentioned by the expert as a supplier for chromatography instruments as well as simple solvents and reagents, providing exposure to the life science tools ecosystem.
- Weaknesses
- Cloud labs do not upgrade instruments frequently, limiting the pull on new instrument sales.
- Comparison
- Compared with a pure instrument replacement-cycle logic, TMO is more likely to benefit indirectly through consumables and installed-base usage.
- Risks
- The cloud lab market is still small, so near-term contribution may be limited.
- AChromatography and mass spectrometry instrument supplier exposure
- Strengths
- Mentioned by the expert as a preferred supplier in both chromatography and mass spectrometry experiments.
- Weaknesses
- Customer focus on same-method reproducibility reduces the need for frequent instrument upgrades.
- Comparison
- Along with WAT, it benefits more from installed instruments and use in workflows than from rapid replacement.
- Risks
- If cloud lab expansion does not translate into new equipment purchases, revenue upside will be limited.
- WATChromatography and mass spectrometry instrument supplier exposure
- Strengths
- Mentioned by the expert in both chromatography and mass spectrometry experiments.
- Weaknesses
- Cloud labs avoid frequent instrument upgrades, which may weaken the contribution from replacement cycles.
- Comparison
- It belongs with A among the core analytical instrument suppliers cited by the expert.
- Risks
- The short-term cloud lab market is small, making it difficult to create a meaningful industry catalyst.
- AVTRVWR channel and consumables exposure
- Strengths
- Simple solvents and reagents are purchased through VWR, providing consumables channel exposure.
- Weaknesses
- Specialized proteins and antibodies are supplied by customers, limiting some high-value consumables opportunities.
- Comparison
- Compared with instrument OEMs, the consumables channel may be more closely tied to growth in lab run volume.
- Risks
- The overall cloud lab market is still small, making procurement contribution uncertain.
- CROPotential competitor and long-term substitution target
- Strengths
- CROs have an outsourced services foundation and may build competitive cloud labs in the future.
- Weaknesses
- The expert believes cloud labs have little near-term impact on CROs.
- Comparison
- The main near-term share donor is more likely to be internal pharma labs than CROs.
- Risks
- If the cloud lab model matures and is expanded by CROs or new entrants, the long-term competitive boundary may change.
Key data
- Current customer mixAlmost entirely from top 10-20 large pharmaceutical companiesThe customer focus is on late-stage development and quality testing; consumer goods, semiconductors, and academic customers have been strategically deprioritized.
- Instrument utilization75%-80%Cloud labs achieve about 75%-80% utilization per instrument, with another 20%-25% reserved for maintenance; typical in-house pharma labs are around 15%.
- Number of market participantsAbout 6-12 credible playersThe expert believes the cloud lab market is still very small.
- The expert company's revenue growthDoubled every year over the past three yearsAbout 50% of growth came from new customers and 50% from existing customers.
- Future growth driverMainly driven by same-site sales ramp over the next 1-3 yearsExpansion plans for existing facilities are already underway, indicating confidence in the demand pipeline.
- Preferred chromatography instrumentsTMO, A, WATThe expert said instruments from these suppliers are more preferred.
- Preferred mass spectrometry instrumentsA, WATMass spectrometry-related experiments favor A and WAT.
- NMR exposureBRKRBRKR is not covered by Morgan Stanley Research.
- Primary liquid-handling supplierHamilton CompanyHamilton Company is privately held.
- Consumables sourcingTMO, VWR (AVTR)Simple solvents and reagents are sourced directly through TMO and VWR, while specialized proteins and antibodies are typically provided by customers.
Impact & implications
For investors, cloud labs are worth tracking as a long-term efficiency innovation theme within Life Science Tools & Diagnostics, but at present they look more like a small-scale, fast-growing complementary service model rather than a disruptor that immediately changes CRO or instrument OEM profit structures. For instrument companies, cloud labs may bring stable usage and consumables purchases, but because they prioritize reproducibility and rarely upgrade instruments, they should not be viewed as a major replacement-cycle catalyst in the near term. For CROs, the short-term impact is limited; the long-term risk is that CROs may build similar capabilities and change the way they compete.
Risks
- The cloud lab market is still small, with only about 6-12 credible players, so the path to scale still needs to be proven.
- Customers are highly concentrated among the top 10-20 large pharmaceutical companies; if large pharma budgets or procurement timing changes, revenue growth may be affected.
- CROs may eventually build cloud labs of their own and create competition.
- Cloud labs rarely upgrade instruments in order to maintain reproducibility, which may weaken incremental demand for instrument OEMs.
- The expert believes DNA sequencing has poor economics and relatively high remote-control technology overhead, showing that not every experiment type is suitable for the cloud lab model.
- AI applications still have constraints; the expert is skeptical about relying on native instrument OEM software, and the labs themselves do not run on LLMs.
- Data security and customer IP ownership are key trust variables, although the expert's company has not had a data incident to date.
What to watch
- Whether same-site sales ramp continues over the next 1-3 years.
- Whether expansion plans for existing facilities can be rolled out as needed and translate into revenue realization.
- Whether large pharmaceutical companies migrate more internal lab work to cloud labs.
- Whether CROs begin building or acquiring cloud lab capabilities.
- Whether cloud lab purchases of TMO, A, WAT, AVTR, and other suppliers expand.
- Whether instrument upgrade cycles remain infrequent or change as new experiment types expand.
- The actual degree of AI adoption in experimental design, results analysis, and lab scheduling.
- Whether data security, customer IP ownership, and temporary local server storage mechanisms remain stable.